12/05/2024, 05:31 PM UTC
辉瑞：低估至不容忽视Pfizer: Too Cheap To Ignore
1、辉瑞的基本面正在改善，第三季度业绩稳健，2024年展望上调；2、根据每股33.39美元的内在价值，股票被低估，具有32%的上涨潜力；3、尽管近期股价走弱，但辉瑞提供了有吸引力的未来股息收益率，这得益于强劲的收入增长和积极的研发支出。1. Pfizer's fundamentals are improving with solid Q3 earnings and upgraded 2024 guidance; 2. The stock is undervalued with a 32% upside potential based on a $33.39 intrinsic value per share; 3. Despite recent share price weakness, Pfizer offers a compelling forward dividend yield supported by strong revenue growth and aggressive R&D spending.---
本文由大语言模型（LLM）生成，旨在为读者提供半导体新闻内容的知识扩展（Beta）。
